BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19239041)

  • 1. Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
    Neyns B; Hoorens A; Stupp R
    Acta Neurol Belg; 2008 Dec; 108(4):131-4. PubMed ID: 19239041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
    Grieco A; Tafuri MA; Biolato M; Diletto B; Di Napoli N; Balducci N; Vecchio FM; Miele L
    Medicine (Baltimore); 2015 Mar; 94(12):e476. PubMed ID: 25816026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
    Sarganas G; Orzechowski HD; Klimpel A; Thomae M; Kauffmann W; Herbst H; Bronder E; Garbe E
    Neuro Oncol; 2012 May; 14(5):541-6. PubMed ID: 22394496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal reactivation of hepatitis B with temozolomide.
    Grewal J; Dellinger CA; Yung WK
    N Engl J Med; 2007 Apr; 356(15):1591-2. PubMed ID: 17429098
    [No Abstract]   [Full Text] [Related]  

  • 5. Temozolomide induced liver injury.
    Dixit S; Hingorani M; Afzal P; Campbell AP
    Acta Neurol Belg; 2011 Sep; 111(3):249-51. PubMed ID: 22141295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced cholestatic hepatitis: how late can it occur even after the cessation of the culpable drug?
    Zamani N; Mohammad Alizadeh A
    Neuro Oncol; 2012 Jul; 14(7):830. PubMed ID: 22544734
    [No Abstract]   [Full Text] [Related]  

  • 7. [Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
    Łata S; Molczyk A
    Przegl Lek; 2010; 67(5):445-6. PubMed ID: 20684359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide-induced biliary ductopenia: a case report.
    Balakrishnan A; Ledford R; Jaglal M
    J Med Case Rep; 2016 Feb; 10():33. PubMed ID: 26846183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide: fatal hepatic failure.
    Prescrire Int; 2014 Sep; 23(152):214. PubMed ID: 25325123
    [No Abstract]   [Full Text] [Related]  

  • 10. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
    Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.
    Chheda MG; Drappatz J; Greenberger NJ; Kesari S; Weiss SE; Gigas DC; Doherty LM; Wen PY
    Neurology; 2007 Mar; 68(12):955-6. PubMed ID: 17372135
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatic encephalopathy after treatment with temozolomide.
    Goldbecker A; Tryc AB; Raab P; Worthmann H; Herrmann J; Weissenborn K
    J Neurooncol; 2011 May; 103(1):163-6. PubMed ID: 20730617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
    Mason M; Adeyi O; Fung S; Millar BA
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
    Cahill DP; Codd PJ; Batchelor TT; Curry WT; Louis DN
    Clin Neurosurg; 2008; 55():165-71. PubMed ID: 19248684
    [No Abstract]   [Full Text] [Related]  

  • 15. [Temozolomide in patients with a glioblastoma multiforme: new developments].
    Bromberg JE; Postma TJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare case of aplastic anemia caused by temozolomide.
    George BJ; Eichinger JB; Richard TJ
    South Med J; 2009 Sep; 102(9):974-6. PubMed ID: 19668033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute temozolomide induced liver injury : Mixed type hepatocellular and cholestatic toxicity.
    Aygun C; Altınok AY; Çakır A; Agan AF; Balaban Y
    Acta Gastroenterol Belg; 2016; 79(4):487-489. PubMed ID: 28209108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.